Philippe Rousselot

11.0k citations
31 papers · 2.3k indexed · 2 hit papers · h-index 16
Topics
Chronic Myeloid Leukemia Treatments (24 papers)Chronic Lymphocytic Leukemia Research (19 papers)Eosinophilic Disorders and Syndromes (14 papers)
Partner nations
FranceSpainRussia

In The Last Decade

Philippe Rousselot

28 papers receiving 2.2k citations

Hit Papers

Discontinuation of imatinib in patients with chronic myel...2010202620152020201020162505007501000

Peers

Philippe Rousselot
Comparison fields: 5 of 66
  • Hematology 2.0k
  • Genetics 1.7k
  • Rheumatology 1.0k
  • Oncology 365
  • Molecular Biology 253
Replace Concepción Boqué with:
Concepción Boqué Spain
Beatriz Moiraghi Argentina
M. Brigid Bradley‐Garelik United States
Philipp D. le Coutre Germany
Kerry Taylor Australia
Albert Hoenekopp Switzerland
Juan Luis Steegmann Spain
Agnès Guerci France
Phuong Dang Australia
P. Le Coutre Germany
Philippe Rousselot relative to Concepción Boqué Spain Concepción Boqué's profile →
Citations per field
00.5×1.5×
Concepción Boqué · 1×
Citations per year

Countries citing papers authored by Philippe Rousselot

Since Specialization
Citations

This map shows the geographic impact of Philippe Rousselot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philippe Rousselot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philippe Rousselot more than expected).

Fields of papers citing papers by Philippe Rousselot

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philippe Rousselot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philippe Rousselot. The network helps show where Philippe Rousselot may publish in the future.

Co-authorship network of co-authors of Philippe Rousselot

This figure shows the co-authorship network connecting the top 25 collaborators of Philippe Rousselot. A scholar is included among the top collaborators of Philippe Rousselot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philippe Rousselot. Philippe Rousselot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 0
2 5
3 2
4 0
5 48
6 18
7 17
8 30
9 23
10
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trialbreakdown →
1046
11 1
12 36
13 1
14
Quelle place a aujourd’hui l’imatinib dans le traitement de la LMC ?
0
15 2
16 154
17 5
18
Stratégies thérapeutiques et recommandations pour la prise en charge des patients atteints de leucémie myéloïde chronique
2
19 9
20 55

About Philippe Rousselot

Philippe Rousselot is a scholar working on Hematology, Genetics and Rheumatology, having authored 31 papers that have together received 2.3k indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (24 papers), Chronic Lymphocytic Leukemia Research (19 papers) and Eosinophilic Disorders and Syndromes (14 papers). The work is most often cited by research in Hematology (2.0k citations), Genetics (1.7k citations) and Rheumatology (1.0k citations). Philippe Rousselot has collaborated with scholars based in France, Spain and Russia. Frequent co-authors include François Guilhot, Joëlle Guilhot, François‐Xavier Mahon, Delphine Réa, Laurence Legros, Franck E. Nicolini, Gabriel Étienne, Aude Charbonnier, Bruno Varet and Françoise Huguet. Their work appears in journals such as Journal of Clinical Oncology, Blood and Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026